Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis.

IF 6.9 1区医学 Q1 IMMUNOLOGY NPJ Vaccines Pub Date : 2024-12-30 DOI:10.1038/s41541-024-01048-y

Gernot Wagner, Gerald Gartlehner, Kylie Thaler, Dominic Ledinger, Johanna Feyertag, Irma Klerings, K M Saif-Ur-Rahman, Declan Devane, Kate Olsson, Karam Adel Ali, Sabine Vygen-Bonnet, Heini Salo, Dace Zavadska, Marta Grgič Vitek, Marje Oona, Robert Cunney, David Tuerlinckx, Frederikke Kristensen Lomholt, Isolde Sommer

{"title":"Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis.","authors":"Gernot Wagner, Gerald Gartlehner, Kylie Thaler, Dominic Ledinger, Johanna Feyertag, Irma Klerings, K M Saif-Ur-Rahman, Declan Devane, Kate Olsson, Karam Adel Ali, Sabine Vygen-Bonnet, Heini Salo, Dace Zavadska, Marta Grgič Vitek, Marje Oona, Robert Cunney, David Tuerlinckx, Frederikke Kristensen Lomholt, Isolde Sommer","doi":"10.1038/s41541-024-01048-y","DOIUrl":null,"url":null,"abstract":"<p><p>Pneumococcal infections are a serious health issue associated with increased morbidity and mortality. This systematic review evaluated the efficacy, effectiveness, immunogenicity, and safety of the pneumococcal conjugate vaccine (PCV)15 compared to other pneumococcal vaccines or no vaccination in children and adults. We identified 20 randomized controlled trials (RCTs). A meta-analysis of six RCTs in infants showed that PCV15 was non-inferior compared with PCV13 for 12 shared serotypes. Based on a meta-analysis of seven RCTs in adults, PCV15 was non-inferior to PCV13 for 13 shared serotypes. For the unique PCV15 serotypes, 22F and 33F, immune responses were higher in infants and adults vaccinated with PCV15 compared to those receiving PCV13. Regarding safety, meta-analyses indicated comparable risks of adverse events between PCV15 and PCV13 in infants. Adults receiving PCV15 had a slightly higher risk of adverse events, though serious events were similar between groups.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"257"},"PeriodicalIF":6.9000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11685527/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-024-01048-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Pneumococcal infections are a serious health issue associated with increased morbidity and mortality. This systematic review evaluated the efficacy, effectiveness, immunogenicity, and safety of the pneumococcal conjugate vaccine (PCV)15 compared to other pneumococcal vaccines or no vaccination in children and adults. We identified 20 randomized controlled trials (RCTs). A meta-analysis of six RCTs in infants showed that PCV15 was non-inferior compared with PCV13 for 12 shared serotypes. Based on a meta-analysis of seven RCTs in adults, PCV15 was non-inferior to PCV13 for 13 shared serotypes. For the unique PCV15 serotypes, 22F and 33F, immune responses were higher in infants and adults vaccinated with PCV15 compared to those receiving PCV13. Regarding safety, meta-analyses indicated comparable risks of adverse events between PCV15 and PCV13 in infants. Adults receiving PCV15 had a slightly higher risk of adverse events, though serious events were similar between groups.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

15 价肺炎球菌结合疫苗的免疫原性和安全性，系统回顾和荟萃分析。

肺炎球菌感染是一个严重的健康问题，与发病率和死亡率增加有关。本系统综述评估了肺炎球菌结合疫苗（PCV）15在儿童和成人中与其他肺炎球菌疫苗或未接种疫苗相比的疗效、有效性、免疫原性和安全性。我们纳入了20项随机对照试验（rct）。一项对6项婴儿随机对照试验的荟萃分析显示，在12种共有血清型中，PCV15与PCV13相比并不逊色。基于7项成人随机对照试验的荟萃分析，PCV15在13种共有血清型中不劣于PCV13。对于独特的PCV15血清型，22F和33F，接种PCV15的婴儿和成人的免疫应答比接种PCV13的婴儿和成人更高。关于安全性，荟萃分析显示PCV15和PCV13在婴儿中的不良事件风险相当。接受PCV15的成年人不良事件的风险略高，尽管两组之间的严重事件相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.